COSMO PHARMACEUTICALS NV (C43.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:C43 - NL0011832936 - Common Stock
48.8 EUR
-1.2 (-2.4%)
Taking everything into account, C43 scores 8 out of 10 in our fundamental rating. C43 was compared to 52 industry peers in the Pharmaceuticals industry. C43 scores excellent points on both the profitability and health parts. This is a solid base for a good stock. C43 is growing strongly while it also seems undervalued. This is an interesting combination Finally C43 also has an excellent dividend rating. These ratings could make C43 a good candidate for value and dividend and growth and quality investing.
1. Profitability
1.1 Basic Checks
C43 had positive earnings in the past year.
In the past year C43 had a positive cash flow from operations.
In multiple years C43 reported negative net income over the last 5 years.
In the past 5 years C43 always reported a positive cash flow from operatings.
1.2 Ratios
C43 has a better Return On Assets (20.60%) than 94.23% of its industry peers.
C43 has a Return On Equity of 26.74%. This is in the better half of the industry: C43 outperforms 76.92% of its industry peers.
C43's Return On Invested Capital of 21.60% is amongst the best of the industry. C43 outperforms 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROIC | 21.6% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of C43 (49.94%) is better than 98.08% of its industry peers.
C43's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 55.81%, C43 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Operating Margin of C43 has grown nicely.
C43 has a Gross Margin of 83.00%. This is amongst the best in the industry. C43 outperforms 86.54% of its industry peers.
C43's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% |
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
2. Health
2.1 Basic Checks
C43 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for C43 has been reduced compared to 1 year ago.
The number of shares outstanding for C43 has been increased compared to 5 years ago.
The debt/assets ratio for C43 has been reduced compared to a year ago.
2.2 Solvency
C43 has an Altman-Z score of 5.80. This indicates that C43 is financially healthy and has little risk of bankruptcy at the moment.
C43 has a Altman-Z score of 5.80. This is amongst the best in the industry. C43 outperforms 90.38% of its industry peers.
C43 has a debt to FCF ratio of 0.01. This is a very positive value and a sign of high solvency as it would only need 0.01 years to pay back of all of its debts.
C43 has a better Debt to FCF ratio (0.01) than 98.08% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that C43 is not too dependend on debt financing.
The Debt to Equity ratio of C43 (0.00) is better than 94.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 5.8 |
ROIC/WACC2.81
WACC7.68%
2.3 Liquidity
A Current Ratio of 4.19 indicates that C43 has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.19, C43 belongs to the top of the industry, outperforming 96.15% of the companies in the same industry.
A Quick Ratio of 3.91 indicates that C43 has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.91, C43 belongs to the top of the industry, outperforming 96.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 1315.29% over the past year.
The Earnings Per Share has been growing by 85.20% on average over the past years. This is a very strong growth
Looking at the last year, C43 shows a very strong growth in Revenue. The Revenue has grown by 187.55%.
Measured over the past years, C43 shows a very strong growth in Revenue. The Revenue has been growing by 33.68% on average per year.
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
3.2 Future
The Earnings Per Share is expected to grow by 29.02% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 22.67% on average over the next years. This is a very strong growth
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 5.98, the valuation of C43 can be described as very cheap.
Based on the Price/Earnings ratio, C43 is valued cheaper than 92.31% of the companies in the same industry.
C43 is valuated cheaply when we compare the Price/Earnings ratio to 26.84, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 8.09, which indicates a very decent valuation of C43.
Compared to the rest of the industry, the Price/Forward Earnings ratio of C43 indicates a rather cheap valuation: C43 is cheaper than 84.62% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.40, C43 is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 |
4.2 Price Multiples
96.15% of the companies in the same industry are more expensive than C43, based on the Enterprise Value to EBITDA ratio.
94.23% of the companies in the same industry are more expensive than C43, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.46 | ||
| EV/EBITDA | 3.83 |
4.3 Compensation for Growth
The excellent profitability rating of C43 may justify a higher PE ratio.
C43's earnings are expected to decrease with -27.68% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
5. Dividend
5.1 Amount
C43 has a Yearly Dividend Yield of 3.85%.
The stock price of C43 dropped by -28.24% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
Compared to an average industry Dividend Yield of 2.20, C43 pays a bit more dividend than its industry peers.
C43's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
5.2 History
On average, the dividend of C43 grows each year by 7.41%, which is quite nice.
Dividend Growth(5Y)7.41%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
24.09% of the earnings are spent on dividend by C43. This is a low number and sustainable payout ratio.
The dividend of C43 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP24.09%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
FRA:C43 (4/29/2025, 7:00:00 PM)
48.8
-1.2 (-2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.98%
Inst Owner ChangeN/A
Ins Owners38.78%
Ins Owner ChangeN/A
Market Cap855.95M
Revenue(TTM)266.79M
Net Income(TTM)133.24M
Analysts84
Price Target104.72 (114.59%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
Yearly Dividend2
Dividend Growth(5Y)7.41%
DP24.09%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-13.87%
Revenue NY rev (3m)-12.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.98 | ||
| Fwd PE | 8.09 | ||
| P/S | 3.21 | ||
| P/FCF | 5.46 | ||
| P/OCF | 5.27 | ||
| P/B | 1.72 | ||
| P/tB | 6.01 | ||
| EV/EBITDA | 3.83 |
EPS(TTM)8.16
EY16.72%
EPS(NY)6.03
Fwd EY12.36%
FCF(TTM)8.94
FCFY18.31%
OCF(TTM)9.26
OCFY18.97%
SpS15.21
BVpS28.41
TBVpS8.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.6% | ||
| ROE | 26.74% | ||
| ROCE | 24.88% | ||
| ROIC | 21.6% | ||
| ROICexc | 28.38% | ||
| ROICexgc | 129.8% | ||
| OM | 55.81% | ||
| PM (TTM) | 49.94% | ||
| GM | 83% | ||
| FCFM | 58.76% |
ROA(3y)6.94%
ROA(5y)4.44%
ROE(3y)9.26%
ROE(5y)6.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y181.33%
ROICexgc growth 5YN/A
ROICexc growth 3Y154.84%
ROICexc growth 5YN/A
OM growth 3Y48.45%
OM growth 5YN/A
PM growth 3Y14.46%
PM growth 5YN/A
GM growth 3Y18.94%
GM growth 5Y6.74%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 46.02% | ||
| Cap/Sales | 2.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.77% | ||
| Profit Quality | 117.65% | ||
| Current Ratio | 4.19 | ||
| Quick Ratio | 3.91 | ||
| Altman-Z | 5.8 |
F-Score8
WACC7.68%
ROIC/WACC2.81
Cap/Depr(3y)45.29%
Cap/Depr(5y)77.05%
Cap/Sales(3y)4.67%
Cap/Sales(5y)8.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1315.29%
EPS 3Y85.2%
EPS 5YN/A
EPS Q2Q%551.15%
EPS Next Y-23.67%
EPS Next 2Y-48.85%
EPS Next 3Y-27.68%
EPS Next 5Y29.02%
Revenue 1Y (TTM)187.55%
Revenue growth 3Y60.05%
Revenue growth 5Y33.68%
Sales Q2Q%165.79%
Revenue Next Year-19.4%
Revenue Next 2Y-19.53%
Revenue Next 3Y-19.24%
Revenue Next 5Y22.67%
EBIT growth 1Y8040.37%
EBIT growth 3Y137.59%
EBIT growth 5YN/A
EBIT Next Year-33.52%
EBIT Next 3Y-14.79%
EBIT Next 5Y28.59%
FCF growth 1Y756.04%
FCF growth 3Y236.69%
FCF growth 5YN/A
OCF growth 1Y615.22%
OCF growth 3Y134.4%
OCF growth 5YN/A
COSMO PHARMACEUTICALS NV / C43.DE FAQ
What is the ChartMill fundamental rating of COSMO PHARMACEUTICALS NV (C43.DE) stock?
ChartMill assigns a fundamental rating of 9 / 10 to C43.DE.
What is the valuation status of COSMO PHARMACEUTICALS NV (C43.DE) stock?
ChartMill assigns a valuation rating of 8 / 10 to COSMO PHARMACEUTICALS NV (C43.DE). This can be considered as Undervalued.
How profitable is COSMO PHARMACEUTICALS NV (C43.DE) stock?
COSMO PHARMACEUTICALS NV (C43.DE) has a profitability rating of 8 / 10.
Can you provide the PE and PB ratios for C43 stock?
The Price/Earnings (PE) ratio for COSMO PHARMACEUTICALS NV (C43.DE) is 5.98 and the Price/Book (PB) ratio is 1.72.
Can you provide the financial health for C43 stock?
The financial health rating of COSMO PHARMACEUTICALS NV (C43.DE) is 9 / 10.